REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B
904.38
USD
1.56
(0.17%)
Post Trading·904.19USD-0.19(-0.02%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
OverviewFinancialsForecastEarningsDividendsCompany

Regeneron Pharmaceuticals executives and insider trading

Leonard S. Schleifer reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Regeneron Pharmaceuticals's insiders sold 62,211 shares for 57.29M USD in 131 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
131
Shares sold
62,211
Value sold
57.29M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
43.32M USD
0
1 month
49.56M USD
0
3 months
52.22M USD
0
6 months
52.35M USD
0
1 year
57.29M USD
0
2 years
61.82M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
George L Sing Director—21,12920.38M USD—2 Nov 202646,276
Huda Y Zoghbi Director—9,0778.50M USD—3 Nov 20269,142
Christine A Poon Director—7,8307.59M USD—2 Nov 202613,049
Jason Pitofsky SVP Controller—6,0985.41M USD—4 Nov 20268,155
Joseph J. LaRosa Executive Vice President, General Counsel & Secretary674,4664.31M USD—2 Nov 202652,058
Andrew J. Murphy Executive Vice President of Research & Co-Chief Scientific Officer684,1473.20M USD—14 Oct 202646,779
Marion Mccourt EVP Commercial—3,4782.99M USD—30 Oct 202610,871
Bonnie L Bassler Director—2,2601.77M USD—7 Jan 20263,203
Michael S Brown Director—1,9291.69M USD—30 Oct 20263,309
Kathryn Guarini Director—1,2001.02M USD—30 Oct 20261,003
Arthur F Ryan Director—597432.54K USD—2 Jul 202617,303

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
4 Nov 2026Jason PitofskySale439939.57412.47K USD7,716Form 4
4 Nov 2026Jason PitofskySale575940.46540.76K USD7,141Form 4
4 Nov 2026Jason PitofskySale982941.58924.63K USD6,159Form 4
4 Nov 2026Jason PitofskySale1,215942.311.14M USD4,944Form 4
4 Nov 2026Jason PitofskySale529943.53499.13K USD4,415Form 4
4 Nov 2026Jason PitofskySale108944.22101.98K USD4,307Form 4
4 Nov 2026Jason PitofskySale35945.6133.10K USD4,272Form 4
4 Nov 2026Jason PitofskySale179950.76170.19K USD—Form 4
3 Nov 2026Huda Y ZoghbiSale6,939970.426.73M USD2,203Form 4
3 Nov 2026Huda Y ZoghbiSale500971.06485.53K USD1,703Form 4
2 Nov 2026George L SingSale1,224960.571.18M USD45,052Form 4
2 Nov 2026George L SingSale540961.85519.40K USD44,512Form 4
2 Nov 2026George L SingSale2,522962.612.43M USD41,990Form 4
2 Nov 2026George L SingSale4,338963.474.18M USD37,652Form 4
2 Nov 2026George L SingSale2,670964.572.58M USD34,982Form 4

Common questions about Regeneron Pharmaceuticals's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.